Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
A Multicenter Study of Ibrutinib and Lenalidomide in Combination With DA-EPOCH-R in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
調査の概要
状態
介入・治療
詳細な説明
This is a Phase 1b, open-label, non-randomized multicenter study conducted in 2 parts. Part 1, will determine the MTD of the combination of ibrutinib, lenalidomide and DA-EPOCH-R in subjects with DLBCL.
Ibrutinib will be administered at a fixed dose of 560 mg and lenalidomide will be dose-escalated. DA-EPOCH-R will be given at standard doses.
For Part 2, the MTD determined in Part 1 will be the dose used for all subjects. If no MTD is identified, then subjects in Part 2 will be treated with the maximum administered doses (MAD, treatment doses from dose Level 4).
The primary objective for Part 2 is to determine the ORR of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with ABC DLBCL as analyzed by gene expression profiling when treated at recommended phase 2 dose (RP2D).
研究の種類
入学 (実際)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- SITE-1
-
Los Angeles、California、アメリカ、90095
- SITE-2
-
Orange、California、アメリカ、92868
- SITE-10
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612
- SITE-3
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21201
- SITE-5
-
Bethesda、Maryland、アメリカ、20892
- SITE-6
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- SITE-4
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87106
- SITE-8
-
-
New York
-
Stony Brook、New York、アメリカ、11794
- SITE-9
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- SITE-7
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Major inclusion criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
- Pathologically confirmed relapsed/refractory DLBCL
- Subjects must have ≥1 measurable disease site on CT scan (≥ 1.5 cm in longest dimension).
Adequate hepatic and renal function:
- AST or ALT ≤2.5 x ULN
- Serum Creatinine ≤ 2.0 mg/dL and creatinine clearance ≥60 mL/min/1.73
- Bilirubin ≤1.5 x ULN
Adequate hematologic function:
- ANC >1,000 cells/mm3
- Platelets ≥75,000 cells/mm3
- Hemoglobin ≥8.0 g/dL
- Prothrombin time (PT) and activated partial thromboplastin time (aPTT) must be ≤1.5 x the upper limit of the normal range (ULN)
- Must be registered into the Revlimid REMS™program and be willing to comply with the requirements of Revlimid REMS™.
Major Exclusion Criteria:
- Known central nervous system lymphoma
- Any chemotherapy, external beam radiation therapy, or anti-cancer antibodies within 2 weeks
- Radio- or toxin-immunoconjugates within 10 weeks
- Prior allogenetic stem cell (or other organ) transplant within 6 months or any evidence of active graft-versus-host disease or requirement for immunosuppressants within 28 days prior to first dose of study drug
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Part 1: Dose Level 1
Ibrutinib 560 mg PO + DA-EPOCH-R
|
イブルチニブ
Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
|
実験的:Part 1: Dose Level 2
Ibrutinib 560 mg (PO) +lenalidomide 15 mg (PO) + DA-EPOCH-R
|
イブルチニブ
Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
レナリドミド
|
実験的:Part 1: Dose Level 3
Ibrutinib 560 mg (PO) +lenalidomide 20 mg (PO) + DA-EPOCH-R
|
イブルチニブ
Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
レナリドミド
|
実験的:Part 1: Dose Level 4
Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
|
イブルチニブ
Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
レナリドミド
|
実験的:Part 2: RP2D
Recommended Phase 2 Dose(RP2D): Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
|
イブルチニブ
Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
レナリドミド
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability
時間枠:1 year after last subjects received the first dose
|
Part-1: To determine the maximum tolerated dose (MTD) of the combination of ibrutinib and lenalidomide with dose adjusted EPOCH-R
|
1 year after last subjects received the first dose
|
Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy-ORR
時間枠:1 year after last subjects received the first dose
|
Part 2 - Overall Response rate will be defined as the proportion of subjects who achieve either a Complete Response or a Partial Response according to the international Working Group Response Criteria for NHL as assessed by investigator.
|
1 year after last subjects received the first dose
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy
時間枠:1 year after last subjects received the first dose
|
Part-1: Overall Response rate (ORR) will defined as the proportion of subjects who achieve either a CR or a PR according to the international Working Group Response Criteria for NHL as assessed by investigator.
|
1 year after last subjects received the first dose
|
Number of Subjects With Adverse Events as a Measure of Safety and Tolerability
時間枠:1 year after last subjects received the first dose
|
Part 2: The frequency (number and percentage) of treatment-emergent adverse events will be reported.
|
1 year after last subjects received the first dose
|
Progression Free Survival (PFS) and Overall Survival (OS) as a Measure of Efficacy
時間枠:From initial dose date until the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 1 year after the last subject received the first dose, up to 36 months at the most.
|
Part 2: PFS will be measured as time from first study drug administration to disease progression or death from any cause.
OS will be measured from the time of first study drug administration until the date of death using Kaplan-Meier methodology.
|
From initial dose date until the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 1 year after the last subject received the first dose, up to 36 months at the most.
|
Duration of Response (DOR)
時間枠:From initial response date until the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 1 year after the last subject received the first dose.
|
Part 2: DOR will be measured from the time by which the measurement criteria are met for CR or PR until the first date by which recurrent or progressive disease is objectively documented.
|
From initial response date until the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 1 year after the last subject received the first dose.
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Jutta Neuenburg, MD、Pharmacyclics LLC (An AbbVie Company)
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。